CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.
Microglial activation, characterized by p38 MAPK or p44/42 MAPK pathway signal transduction, occurs in Alzheimer's disease (AD). Our previous studies demonstrated CD45, a membrane-bound protein tyrosine phosphatase (PTP), opposed beta-amyloid (Abeta) peptide-induced microglial activation via in...
Main Authors: | Yuyan Zhu, Huayan Hou, William V Nikolic, Jared Ehrhart, Elona Rrapo, Paula Bickford, Brian Giunta, Jun Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-05-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2366070?pdf=render |
Similar Items
-
Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression
by: Bickford Paula, et al.
Published: (2008-09-01) -
Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD)
by: Jin Jingji, et al.
Published: (2011-01-01) -
Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo.
by: Leila M Luheshi, et al.
Published: (2010-03-01) -
Specific Binding of Alzheimer’s Abeta Peptide Fibrils to Single Walled Carbon Nanotubes
by: Steingrimur Stefansson, et al.
Published: (2012-10-01) -
Is Abeta a sufficient Biomarker for monitoring anti-Abeta clinical studies? A critical review.
by: Jens eMoreth, et al.
Published: (2013-07-01)